Cerebral toxoplasmosis in HIV-infected patients presenting with sulfamethoxazole-trimethoprim intolerance;Toxoplasmose cerebrale chez les patients infectes par le VIH intolerants au cotrimoxazole

Annales de Medecine Interne

Volumn 149, Issue 2, 1998, Pages 62-66

  Rabaud, Christian ^a,e   May, Thierry ^a   Beuscart, Claude ^b   Reynes, Jacques ^c   Leport, Catherine ^d   Canton, Philippe ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d BICHAT HOSPITAL   (France)

^e CHU NANCY BRABOIS   (France)

Author keywords

Adverse reactions; HIV; Sulfamethoxazole trimethoprim; Toxoplasmosis

Indexed keywords

COTRIMOXAZOLE; PENTAMIDINE ISETHIONATE; PENTAMIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; TOXOPLASMOSIS; AIDS RELATED COMPLEX; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG ERUPTION; FOLLOW UP; MORTALITY; PROBABILITY; PROSPECTIVE STUDY; RISK; SURVIVAL RATE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; MULTICENTER STUDIES; PENTAMIDINE; PNEUMONIA, PNEUMOCYSTIS; PROBABILITY; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK; SURVIVAL RATE; TOXOPLASMOSIS, CEREBRAL; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0031980613     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. SCHNEIDER MME, HOEPELMAN AI, SCHATTENKERK JK : A controlled trial of aerosolized pentamidine or trimethoprim sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med, 1992 ; 327 : 1842-8.
2. OKSENHENDLER E, CHARREAU I, TOURNERIE C, AZIHARY M, CARBON C, ABOULKER JP : Toxoplasma gondii infection in advanced HIV infection. AIDS, 1994 ; 8 : 483-7.
3. MAY Th, BEUSCART C, REYNES J, et al.: Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical study. J Acquir Immune Defic Synd, 1994 ; 7 : 475-82.
4. FISCHL MA, DICKINSON GM, LA VOIE L : Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA, 1998 ; 259 : 1185-9.
5. RUSKIN J, LARIVIERE M : Low dose cotrimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet, 1991 ; 337 : 468-71.
6. SCHNEIDER MME, HOEPELMAN AI, SCHATTENKERK JK : A controlled trial of aerosolized pentamidine or trimethoprim sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med, 1992 ; 327 : 1836-41.
7. LEPORT C, CHENE G, MORLAT P, et al. : Pyrimethamine for primary prophylaxis of toxoplasmosic encephalitis in patients with human immunodeficiency virus infection: a double blind, randomized trial. J Infect Dis, 1996 ; 173 : 91-7.
8. ROUSSEAU F, PUEYO S, MORLAT P, et al. : Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. Clin Infect Dis, 1997 ; 24 : 396-402.
9. HAWKEN M, NUNN P, GATHUA S, et al. : Increased recurrence of tuberculosis in HIV-1 infected patients in Kenya. Lancet, 1993 ; 342 : 332-7.
10. VAN DER VEN AJAM, KOOPMANS PP, VREE TB, VAN DER MEER JSW : Adverse reactions to co-trimoxazole in HIV infection. Lancet, 1991 ; 338 : 431-3.
11. RIEDER MJ, KRAUSE R, BIRD IA, DEBAKAN GA : Toxicity of sulfonamide-reactive metabolites in HIV-Infevted, and noninfected cells. AIDS Res Hum Retroviruses, 1995 ; 8 : 134-40.
12. KOOPMANS PP, VAN DER VEN AJAM, VREE TB, VAN DER MEER JWM : Pathogenesis of hypersensitivity reactions to drugs in patients with HIV Infection: allergic or toxic? AIDS, 1995 ; 9 : 217-22.
13. ROUJEAU JC : Toxidermies au ours de l'infection à VIH. Presse Med, 1994 ; 23 : 111-2.
14. FAUCI AS : Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science, 1993 ; 262 : 1011-8.
15. FULTZ Pn, GLUCKMAN JC, MUCHMORE E, GIRARD M : Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulaton. AIDS Res Hum Retroviruses, 1992 ; 8 : 313-7.
16. CAUMES E, GUERMONPREZ G, WINTER C, KATLAMA C, BRICAIRE F : A life-threatening adverse reaction during trimethoprim-sulfamethoxazole desensitization in a previously hypersensitive patient infected with human immunodeficiency virus. Clin Infect Dis, 1996 ; 23 : 1313-4.
17. GIRARD PM, LANDMAN R, GAUDEBOUT C, et al. : Dapsonepyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med, 1993 ; 328 ; 1514-20.
18. KATLAMA C, MOUTHON B, GOURDON D, LAPIERRE D, ROUSSEAU F and the atovaquone expanded access group : Atovaquone as long term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. AIDS, 1996 ; 10 : 1107-12.
19. LACASSIN F, SCHAFFO D, PERRONE C, LONGUET P, LEPORT C, VILDE JL : Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother, 1995 ; 39 : 276-7.
20. SELLAL A, RABAUD C, AMIEL C, HOEN B, MAY T, CANTON P : Traitement d'entretien de la toxoplamose cérébrale au cours du SIDA : place de l'association clarithromycine-minocycline. Presse Med, 1996 ; 25 : 509.